Cefpiramide (SR 95445) (CPM) is a new cephalosporin with activity against Pseudomonas and a good bioavailability following parenteral administration. This drug is a first rather than second choice treatment in Pseudomonas infections. For this reason, investigation into cefpiramide's capacity to induce beta-lactamase production is especially interesting. A heavy inoculum of P. aeruginosa NCTC 8203, a strain that produces and inducible cephalosporinase (pI = 8.7) was incubated for 4 hours with CPM, cefsulodin (CFS), cefoperazone (CPZ) and ceftazidime (CTZ) in various concentrations. After collection and sonic treatment of the bacteria, the beta-lactamase activity was assayed using an acidimetric method and expressed as units of enzyme activity per mg proteins in the cell-free extract. The smallest increase in beta-lactamase production was recorded with CPM. The strongest inductor was CTZ. CFS and CPZ had an intermediate effect.
Download full-text PDF |
Source |
---|
J Water Health
January 2025
Department of Biology and Ecology, Faculty of Science, University of Kragujevac, Kragujevac 34000, Serbia.
Extended spectrum -lactamase (ESBL)-producing Enterobacteriaceae, including and , pose a serious risk to human health because of antibiotic resistance. Wastewater serves as a reservoir for these bacteria, contributing to the evolution and transmission of antibiotic-resistant strains. The research aims to identify ESBL bacterium in wastewater samples from District Kohat.
View Article and Find Full Text PDFAnn Clin Microbiol Antimicrob
January 2025
Laboratoire de Bactériologie, CHU Félix Guyon, Allée des Topazes, 97400, Saint-Denis, La Réunion, France.
Aim: Located in the Southwest Indian Ocean area (SIOA), the two French overseas territories (FOTs) of Reunion and Mayotte islands are heavily impacted by antimicrobial resistance. The aim of this study was to investigate all cases of NDM-5 and OXA-181 carbapenemase-producing Escherichia coli (CPEc) in these two FOTs between 2015 and 2020, to better understand the regional spread of these last-line treatment resistant bacteria.
Methods: All E.
Infect Dis (Lond)
January 2025
Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain.
Background: Multidrug-resistant bacteria (MDR) represent a significant global health concern and vary in specific settings. Spain reported several annual deaths attributed to MDR bacteria, mainly carbapenemase-producing Enterobacterales.
Objectives: We aimed to characterise the incidence and temporal trends of MDR bacterial infections or colonisations reported within the province of Granada (data from five hospitals), and to investigate factors linked to clinical vulnerability.
Antimicrob Agents Chemother
January 2025
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ceftriaxone-resistant Enterobacterales remain a public health threat; contemporary data investigating their molecular epidemiology are limited. Five hundred consecutive ceftriaxone-resistant (MIC ≥ 4 µg/mL) Enterobacterales bloodstream isolates were collected between 2018 and 2022 from three Maryland hospitals. Broth microdilution confirmed antibiotic susceptibilities.
View Article and Find Full Text PDFJ Med Microbiol
January 2025
Laboratory of Molecular Microbiology (Micromol), Institute of Biomedical Sciences, Universidade Federal de Uberlndia, Uberlndia, Minas Gerais, Brazil.
In critically ill patients, the occurrence of multidrug-resistant infection is a significant concern, given its ability to acquire multidrug-resistant, form biofilms and secrete toxic effectors. In Brazil, limited data are available regarding the prevalence of dissemination, and the impact of the type III secretion system (T3SS) on toxin production and biofilm formation in clinical isolates of . This study investigates the dissemination of virulent harbouring the and genes, the presence of T3SS genes and their biofilm-forming capability.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!